Are the Antagonists of the Renin–Angiotensin System Also Anticancer Agents?

Chiara Lonati, Alberto Morganti

Research output: Contribution to journalArticlepeer-review


The antagonists of the renin–angiotensin system (RAS) have gained increasing popularity in the last two decades due to their indisputable efficacy in a number of cardiovascular disorders, coupled with an unsurpassed tolerability. However some years ago a partial and non-predefined meta-analysis raised the possibility that angiotensin receptor antagonists in particular may increase the incidence of cancer. This observation, although not confirmed by subsequent, larger analyses, caused a remarkable and understandable concern even outside the medical community. Herein we will summarize the available evidence pro and con the hypothesis of a carcinogenetic activity of RAS antagonists coming to the conclusion that these drugs may actually exert an anticancer action.

Original languageEnglish
Pages (from-to)99-102
Number of pages4
JournalHigh Blood Pressure and Cardiovascular Prevention
Issue number2
Publication statusPublished - Jun 11 2015


  • Cancer
  • Renin-angiotensin system
  • Renin-angiotensin system antagonists

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine


Dive into the research topics of 'Are the Antagonists of the Renin–Angiotensin System Also Anticancer Agents?'. Together they form a unique fingerprint.

Cite this